MedPath

Automated Lamellar Keratectomy in Symptomatic Patients With Bullous Keratopathy

Not Applicable
Completed
Conditions
Corneal Disease
Interventions
Procedure: ALK (automated lamellar keratectomy)
Drug: Mitomycin
Registration Number
NCT00654888
Lead Sponsor
Federal University of São Paulo
Brief Summary

To relieve pain in patients with symptomatic bullous keratopathy (BK) until keratoplasty and in patients without visual prediction.

The automated lamellar keratectomy represents a alternative in treatment of pain in symptomatic patients with BK.

Detailed Description

Only patients with BK symptomatic (with pain) were submitted to automated lamellar keratectomy (ALK).

Complete ophthalmological examination including UCVA,BSVA, biomicroscopy, tonometry, esthesiometry, UBM pachymetry, impression cytology and pain questionnaire were performed in preoperative, postoperative of one, seven, 30, 90, 180 days and one year.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
28
Inclusion Criteria
  • Patient with bullous keratopathy symptomatic (with pain)
Read More
Exclusion Criteria
  • herpetic endotelial disorders
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2ALK (automated lamellar keratectomy)automated lamellar keratectomy without mitomycin
1MitomycinGroup one submitted to automated lamellar keratectomy(ALK) with mitomycin (0,02% in 30 seconds after keratectomy).
Primary Outcome Measures
NameTimeMethod
Pain questionnairepreoperative and postoperative 1,7,30,90,180 days and one year
Secondary Outcome Measures
NameTimeMethod
biomicroscopy, esthesiometry, UBM pachymetry, impression cytologypreoperative, postoperative 1,7,30,90,180 days and one year
© Copyright 2025. All Rights Reserved by MedPath